Muscarinic cholinergic receptors can presently be biologically categorized into at least five subtypes (m 1 -m 5 ) and pharmacologically divided into four subtypes (M 1 -M 4 ) by different selective antagonists 1-6) M 2 (m 2 ) muscarinic receptors are abundant in the heart, smooth muscle and the central nervous system and play a crucial role in the regulation of the heart rate mediated by the vagus nerve. In the heart, an increase in parasympathetic tone is thought to be a significant factor in sick sinus syndrome and atrioventricular block, and this implies that M 2 muscarinic receptor antagonists are promising candidates as antibradycardiac agents. Atropine, a non-specific muscarinic receptor antagonist, has been used for treatment of these diseases, though undesirable side effects such as dry mouth, mydriasis and gastrointestinal and urinary events caused by antagonism of the M 3 muscarinic receptors have appeared.
7)
To achieve an effective and safer therapy for such diseases, selective M 2 muscarinic receptor antagonists are required, and AF-DX 116 (1) was reported as the first selective M 2 muscarinic receptor antagonist by Engel et al. 8, 9) AF-DX 116 includes a 5,11-dihydro-6H-pyrido [2,3-b] [1, 4] benzodiazepin-6-one skeleton and two nitrogen atoms protonated at physiological pH, and the spatial orientation of the nitrogen atom in the side chain of the tricyclic ring system is thought to be the most important factor in determining M 2 selectivity over other muscarinic receptor subtypes, especially M 3 muscarinic receptors. 10) We previously designed succinamide derivatives based on the assumption that cleavage of the piperidine ring of 1 would give compounds with sufficient flexibility for interacting with M 2 muscarinic receptors and discovered YM-43571 (2), which showed a higher M 2 affinity than AF-DX 116 and significant M 2 selectivity over M 3 muscarinic receptors (pKi(M 2 )ϭ8.8, M 3 /M 2 selectivityϭ320).
11) Furthermore, we discussed how the two amino nitrogen atoms of YM-43571, a benzylamino nitrogen atom and an alkyl-bearing nitrogen atom of a piperazine ring, play a crucial role in the interaction with M 2 muscarinic receptors, and the importance of the latter for M 3 muscarinic receptor affinity was less than that for M 2 receptors. 11) As another strategy for changing the spacial position of the terminal diethylamino group, we designed 1,2,3,4-tetrahydroisoquinoline derivatives 3a-f, which have the piperidine ring shown in 1 and an alkyl side chain of the proper length (Fig. 1) . Herein, we describe the synthesis and biological evaluation of these compounds.
Chemistry
1,2,3,4-Tetrahydroquinoline (7), 1,2,3,4-tetrahydroisoquinoline (11, 15) and indoline (16) derivatives were prepared by the multi-step routes shown in Chart 1.
12) Diamines 6, 10 and 14a, b were synthesized from the corresponding acids (4, 8 and 12a, b) by the respective methods indicated. Though reduction of 2-(diethylaminomethyl)quinoline with platinum oxide (PtO 2 ), NiCl 2 -NaBH 4 or Ni-Al alloy resulted in recovery of starting material, the desired diamine 6 was obtained by reduction of quinoline-2-carboxylic acid diethylamide 5 with Ni-Al catalyst, followed by treatment with LiAlH 4 .
13) Catalytic hydrogenation of 5 over PtO 2 resulted in over-reduction to decahydroquinoline, however, 1,2,3,4-tetrahydroisoquinoline derivative 10 was obtained from 9 under the same conditions, followed by reduction using BH 3 · THF.
14) The resulting diamines 6, 10 and 14a, b were treated with 11-(chloroacetyl)-5,11-dihydro-6H-pyrido [2,3-b] [1, 4] benzodiazepin-6-one 17, which was prepared according to the method reported by Schmidt, 15) in the presence of sodium carbonate in acetonitrile to give the target compounds 7, 11, 15 and 16, respectively. 1,2,3,4-Tetrahydroisoquinoline derivatives 3a-f were synthesized from 5-hydroxyisoquinoline 18 as shown in Chart 2. Compound 18 was hydrogenated over PtO 2 and subsequently protected with a Boc group to afford 19. After treatment of 19 with an excess amount of dibromoalkanes with different methylene chain lengths (nϭ2-7) in the presence of tetra-nbutylammonium hydrogensulfate in sodium hydroxide solution, the resulting compounds were reacted with an excess of diethylamine and then deprotected by acid to afford diamines 20a-f. Treatment of these diamines with 17 gave the desired compounds 3a-f, according to the above-mentioned method.
Pharmacological Results and Discussion
The muscarinic receptor binding affinity and selectivity were assessed by employing receptor-binding assays, as reported previously.
16) The binding affinities for synthesized compounds were obtained by using rat cerebral cortex (M 1 ), heart (M 2 ) and submandibular gland (M 3 Tables 1 and 2 . AF-DX 116 (1) was used as the reference compound.
Before the biological evaluation of compounds 3a-f, we focused our efforts on investigating the effect of a fused benzene ring by comparison of 7, 11, 15, 16 and 1 (Table 1) . Except for 16, these compounds showed higher affinities for all three subtypes than AF-DX 116, and compounds 7 and 15 were found to have similar M 3 /M 2 selectivity to that of AF-DX 116, in particular. On the other hand, compound 11 displayed a higher affinity for M 1 muscarinic receptors than M 2 and M 3 muscarinic receptors. In addition, we found that there was a significant difference in binding affinities between 7 and 16, though it was reported that exchange of the piperidine ring in AF-DX 116 with the corresponding pyrrolidine lead to a compound with similar affinity for M 2 and M 3 muscarinic receptors. 8) These results suggest that a benzene ring attached to a piperidine ring might play an important role in increasing the affinity for muscarinic receptors probably by p-p and/or p-H interactions, and that its spatial position in relation to the tricyclic ring system or the terminal amino moiety influences both the affinity and subtype selectivity. Furthermore, from comparison of 7 and 15, we obtained the information that the basicity of the nitrogen atom in the piperidine ring (pKa (7)ϭ0.58Ϯ0.40 vs. pKa (15)ϭ4.36Ϯ 0.40) 17) does not greatly affect binding to muscarinic receptors.
Based on the results in Table 1 , we evaluated the structure-activity relationships (SAR) of 5-[(diethylamino)-alkoxy]-1,2,3,4-tetrahydroisoquinoline derivatives 3a-f by changing the alkyl length of the side chain. The results are shown in Table 2 .
The first peak in affinity for the three muscarinic receptors appeared at 2 or 3 methylenes, and compound 3a showed a 6-fold higher affinity for M 2 muscarinic receptors than that of 15. An outstanding increase in M 1 and M 2 affinity was observed when the alkyl linker chain length was 7, while there was no great difference in M 3 affinity between 3a and 3f. This finding suggests two possibilities; the first is that the terminal amino moieties of 3a and 3f recognize the same site on the receptors, and the second is that they interact with different sites. In the former case, it may be inferred that the hydrophobic interaction of the alkyl linker chain with the M 2 muscarinic receptor contributes to the increase in the M 2 affinity. As a result, we discovered compound 3f having a high affinity for M 2 muscarinic receptors (pKiϭ9.1), comparable to that of 2, with M 3 /M 2 selectivity (M 3 /M 2 ϭ50) which was 3-fold larger than that of 1, and our strategy was successful.
The in vivo M 2 muscarinic receptor antagonistic activity of compound 3f was next evaluated. Oxotremorine-induced bradycardia in pithed rat as a marker of M 2 antagonistic activity was assessed in comparison with 1. 16) Compound 3f was given by intravenous administration, and the data are presented as pDR 10 values, as shown in Table 3 .
Compound 3f acted as a noncompetitive antagonist, comparable to 2, in this model, and this behavior was different from 1, which exhibited competitive antagonism.
10) The pDR 10 value of 3f, which was calculated from the ED 30 value, was almost equal to that of 1. We believed that this might be due to plasma protein binding or differences in the distribution to tissues.
Conclusions
In conclusion, we designed novel M 2 muscarinic receptor antagonists 3a-f having 1,2,3,4-tetrahydroisoquinoline units, based on the assumption that a change in spatial location of the terminal amino moiety might lead to compounds with higher affinity and selectivity for M 2 muscarinic receptors and evaluated them for binding affinities to M 1 , M 2 and M 3 muscarinic receptors in vitro, and for antagonism of bradycardia in vivo. Furthermore, we examined the effect of the fused benzene ring in the 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydroquinoline moieties on muscarinic receptor affinity and selectivity by comparison of 7, 11, 15, 16 and 1. As a result, compound 3f, which has a 7-(diethylamino)heptyloxy moiety, without an "accessory portion" such as the 4-(4-alkylpiperazin-1-yl)benzylamino group in succinamide derivatives, showed the highest affinity for M 2 muscarinic receptors (pKiϭ9.1) with 50-fold M 2 selectivity 674
Vol. 47, No. 5 over M 3 receptors and comparable in vivo activity to AF-DX 116. In addition, we obtained SAR indicating that the benzene ring fused piperidine and alkyl linker chain length are crucially important for increasing M 2 affinity. We expect that this knowledge will be useful for the discovery of novel M 2 muscarinic receptor antagonists.
Experimental
All melting points were measured with a Yanaco MP-500D melting point apparatus without correction.
1 H-NMR spectra were obtained on a JEOL JNM-EX90 or JNM-A500 spectrometer and the chemical shifts are expressed in d (ppm) values with tetramethylsilane as an internal standard. Abbreviations of 1 H-NMR signal patterns are as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; q,quartet; m,multiplet; br,broad. Mass spectra were obtained on a JEOL JMS-DX300 or Hitachi M-80 spectrometer. High-resolution mass spectra (HR-MS) were recorded on VG ZAB-VSE mass spectrometers. Column chromatography on silica gel was performed with Kieselgel 60 (E.Merck).
Quinoline-2-carboxylic Acid Diethylamide (5) A mixture of quinoline-2-carboxylic acid (4) (5.0 g, 28.9 mmol), 1-ethyl-3-[3-(dimethylamino)-propyl]carbodiimide hydrochloride (WSCD) (6.1 g, 31.8 mmol), 1-hydroxybenzotriazole (HOBT) (1.95 g, 14.4 mmol) and diethylamine (3.3 ml, 31.8 mmol) in CH 2 Cl 2 (100 ml) was stirred at room temperature for 5 h. After the mixture was washed with 5% citric acid, 5% NaHCO 3 aq. and brine, the organic layer was dried over MgSO 4 , and the solvent was evaporated in vacuo to give 7.5 g of 5 as an oil in 99% yield. Isoquinoline-1-carboxylic Acid Diethylamide (9) The title compound was prepared in the same manner as described for 5 in 68% yield. 1) A solution of 9 (3.0 g, 13.1 mmol) in EtOH (120 ml) was acidified with conc. HCl (1.37 ml) , and was hydrogenated over PtO 2 (300 mg) at 3.0 kgf/cm 2 for 1.5 h. The reaction mixture was filtered through Celite ® , solvent evaporated off, and the product crystallized from acetone to give 1. 2) A suspension of 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid diethylamide hydrochloride (800 mg, 2.98 mmol) in THF (10 ml) was added to BH 3 · THF (20.8 ml, 17.9 mmol) and refluxed for 7 h. After cooling, conc. HCl (1.5 ml) was added and the mixture was refluxed for another 1 h. After cooling to room temperature, the solvent was evaporated in vacuo. The residue was diluted with H 2 O (10 ml) and then poured into KOH aq. The mixture was extracted with CHCl 3 (20 mlϫ3), dried over MgSO 4 and evaporated. The residue was purified on a silica gel column (CHCl 3 -MeOH-NH 4 11-{[1-(Diethylaminomethyl)-1,2,3,4-tetrahydro-2-isoquinolyl]-acetyl}-5,11-dihydro-6H-pyrido[2,3-b][1,4 ]benzodiazepin-6-one (11) The title compound was prepared in the same manner as described for 7 in 63% yield. mp 174-175°C. 3-Diethylaminomethyl-1,2,3,4-tetrahydroisoquinoline (14a) The title compound was prepared in the same manner as described for 10 in 55% yield from 13a. 2-tert-Butyloxycarbonyl-5-hydroxy-1,2,3,4-tetrahydroisoquinoline (19) A suspension of 18 (2.0 g, 12.4 mmol), conc. HCl (1.5 ml) and platinum oxide (500 mg) in methanol (100 ml) was hydrogenated at 3.0 kgf/cm 2 for 3.5 h. The reaction mixture was filtered through Celite ® and the solvent was evaporated to afford 2.42 g of 5-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride as a yellow solid in 99% yield. A mixture of this salt (2.40 g, 12.9 mmol), triethylamine (1.31 g, 12.9 mmol), (Boc) 2 O (3.0 g, 13.7 mmol) in 1,4-dioxane-H 2 O (25 mlϪ25 ml) was stirred for 18 h at room temperature, then concentrated in vacuo. The residue was dissolved in CHCl 3 and washed with 5% citric acid and brine. The extract was dried over MgSO 4 and evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl 3 -MeOH, 40 : 1, v/v) to give 2.60 g of 19 as an amorphous solid in 80% yield. , tetra-n-butylammonium hydrogensulfate (34 mg, 0.1 mmol) and 1 N NaOH aq. (6 ml) was heated at 60°C for 2 h. After cooling, the mixture was extracted with CHCl 3 (10 mlϫ3) and then washed with brine. The extract was dried over MgSO 4 and evaporated in vacuo and the residue was purified by silica gel column chromatography (n-hexane-AcOEt, 10 : 1, v/v) to give 800 mg of N-tert-butyloxycarbonyl-5-(7-bromoheptyloxy)-1,2,3,4 -tetrahydroisoquinoline as an oil in 94% yield. 2) A mixture of N-tert-butyloxycarbonyl-5- (7-bromoheptyloxy)-1,2,3,4 tetrahydroisoquinoline (800 mg, 1.88 mmol) and diethylamine (300 mg, 4.14 mmol) in EtOH (20 ml) was refluxed for 3 h and solvent was evaporated in vacuo. The residue was dissolved in CHCl 3 (15 ml) and washed with brine. The extract was dried over MgSO 4 The title compound was prepared in the same manner as described for 7 as an amorphous solid in 64% yield. 1 Heart Rate Male Wistar rats (300-350 g) were anesthetized with pentobarbital (60 mg/kg i.p.). A tracheal cannula was inserted to allow artificial respiration with room air. A jugular vein was cannulated for i.v. administration of drugs. Rats were pithed by the introduction of a blunt steel rod via the orbit into the spinal canal and were pretreated with atenolol (10 mg/kg i.v.) to exclude catecholamine-induced tachycardia. The test compound or saline was administered i.v.. At 15 min thereafter, a cumulative administration of oxotremorine was carried out. Log dose-response curves were constructed by plotting the decrease in heart rate (percentage of the initial value) vs. the logarithm of the dose (moles per kilogram). The ED 50 values, doses of oxotremorine required to produce a 50% decrease in heart rate, were calculated from the log dose-response curves, and the dose-ratio was calculated. The antagonism for M 2 muscarinic receptors was expressed as the pDR 10 value, the negative logarithm of the DR 10 value, which is the dose of the test compound required to produce the oxotremorine dose-ratio of 10. In the case of compound 3f, the maximum decrease in heart rate of oxotremorine was about 60%. Therefore, the dose-ratio was calculated from ED 30 values, i.e., the doses of oxotremorine required to produce a 30% decrease in heart rate.
